Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10002–10004.

https://doi.org/10.1182/blood-2022-163661

Published: 2022

Journal Articles

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 289–291.

https://doi.org/10.1182/blood-2022-158219

Published: 2022

Journal Articles

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Blood (2022) 140 (Supplement 1): 4287–4289.

https://doi.org/10.1182/blood-2022-168843

Published: 2022

Journal Articles

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Ashish Patel, Adam C. Smith, Esther Masih-Khan, Peace Samuel, Katherine Lajkosz, Sita Bhella, Christine I. Chen, Anca Prica, Donna E. Reece, A. Keith Stewart, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, Vishal Kukreti

Blood (2022) 140 (Supplement 1): 4354–4355.

https://doi.org/10.1182/blood-2022-167113

Published: 2022

Journal Articles

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Richard Leblanc, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Michael P. Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha L Louzada, Hira S Mian, Darrell J White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Rayan Kaedbey, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7192–7194.

https://doi.org/10.1182/blood-2022-158679

Published: 2022

Journal Articles

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Eyal Lebel, Katherine Lajkosz, Esther Masih-Khan, Donna E. Reece, Suzanne Trudel, Rodger E Tiedemann, Anca Prica, Vishal Kukreti, Christine I. Chen

Blood (2021) 138 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2021-151862

Published: 2021

Journal Articles

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Hira S Mian, Richard Leblanc, Martha L Louzada, Esther Masih-Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Michael Sebag, Darrell J White, Muhammad Aslam, Kevin W Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna E. Reece

Blood (2021) 138 (Supplement 1): 4721.

https://doi.org/10.1182/blood-2021-148191

Published: 2021

Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-133372

Published: 2020

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, MD BSc, Christopher P. Venner, MD, Martha L Louzada, MDMSc, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Victor Jimenez-Zepeda, MD, Rami Kotb, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Hira S Mian, MD, Darrell J White, MD, Julie Stakiw, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-142800

Published: 2020

Journal Articles

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

Sahar Khan, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD, Esther Masih-Khan, PhD, Lavinia Aileen Jeyanathan, Anca Prica, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2019) 134 (Supplement_1): 5704.

https://doi.org/10.1182/blood-2019-130733

Published: 2019

Journal Articles

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Martha L Louzada, MDMSc, Darrell J White, MD, Julie Stakiw, MD, Tony Reiman, MD, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 1886.

https://doi.org/10.1182/blood-2019-125479

Published: 2019

Journal Articles

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Darrell J White, MD, Hannah Cherniawsky, BSc,MD, Tony Reiman, MD, Julie Stakiw, MD, Martha L Louzada, MDMSc, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 3173.

https://doi.org/10.1182/blood-2019-125810

Published: 2019

Journal Articles

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Victor Jimenez-Zepeda, MD, Donna E Reece, MD, McCurdy R Arleigh, MD MHA, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Michael Sebag, MD PhD, Julie Stakiw, MD FRCPC, Kevin Song, MD, Richard Leblanc, MDFRCPC, Tony Reiman, MD, Martha L Louzada, MD, Rami Kotb, MD, Engin Gul, BSc, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2018-99-117363

Published: 2018

Journal Articles

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Chloe Yang, MD BS, Haiyan Jiang, PhD, Esther Masih-Khan, PhD, Christine I Chen, MD FRCP(C), Anca Prica, MD FRCP(C), Donna Reece, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3462.

https://doi.org/10.1182/blood.V130.Suppl_1.3462.3462

Published: 2017

Journal Articles

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Donna Reece, BA, MD, John Mikhaeil, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Anca Prica, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 2010.

https://doi.org/10.1182/blood.V130.Suppl_1.2010.2010

Published: 2017

Journal Articles

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Amanda Li, MD BSc, Eshetu G Atenafu, M.Sc., P.Stat, Rosanne St. Bernard, MD MSc, Esther Masih-Khan, PhD, Donna Reece, MD FRCP(C), Norman Anthony Franke, MD, Rodger Tiedemann, MBChB, PhD, Anca Prica, MD FRCP(C), Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 4537.

https://doi.org/10.1182/blood.V130.Suppl_1.4537.4537

Published: 2017

Journal Articles

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Sara Farshchi Zarabi, MD, Esther Masih-Khan, PhD, Christine Chen, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 5821.

https://doi.org/10.1182/blood.V128.22.5821.5821

Published: 2016

Journal Articles

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Henry Siu Him Chan, MBChB, Madeline Phillips, Sophia Farooki, MD FRCPC, Giovanni Piza Rodriguez, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 3457.

https://doi.org/10.1182/blood.V128.22.3457.3457

Published: 2016

Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2016) 128 (22): 2137.

https://doi.org/10.1182/blood.V128.22.2137.2137

Published: 2016

NARROW

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only